SOSAFE
6.7.2022 09:02:14 CEST | Business Wire | Press release
SoSafe – a leading provider of cyber security awareness – has hired former Smartly.io exec and experienced SaaS operator Felix Fichtl as CFO.
Fichtl brings with him more than a decade’s experience in building and scaling finance organisations across the SaaS industry. From both his previous role as CFO at the global social media advertising automation giant, Smartly.io to his time spearheading finance operations for market leaders zoovu (formerly SMARTASSISTANT) and SAP Hybris (now SAP CX).
His appointment comes as SoSafe looks to build on its recent growth and bring its human-centric approach to cybersecurity to the assistance of even more companies on an international scale. SoSafe is currently the market leader in cybersecurity awareness in its home country of Germany, and is one of the leading providers across Europe.
In January 2022, the company closed a $73 million Series B financing round, led by Highland Europe, to help fuel expansion into new territories and establish the firm as the global market leader. Part of these plans involve further bolstering the strength, experience and expertise of the existing C-suite team, of which Fichtl will now play a pivotal role.
With its data-driven and human-centric platform, SoSafe takes a unique, behavioural science approach to cybersecurity. An approach pioneered by its founder and CEO, psychologist Hellemann. Founded on the idea that 85% of cyberattacks on companies and organisations can be traced back to a human factor, SoSafe embeds deep gamification elements into the workflows of employees to foster and scale effective corporate security cultures.
SaaS industry leader Felix Fichtl from Smartly.io strengthens SoSafe's leadership team
During his tenure at Smartly.io, Fichtl scaled the finance organization and played a key role in the sale of a majority stake of the company to Providence Equity in 2019. During his time at SAP Hybris, he managed the post-merger integration of the Hybris side before taking responsibility as Division CFO for SAP Hybris (now SAP CX).
"SoSafe has a crystal-clear value proposition that addresses a key concern for companies worldwide. The company is well on its way to becoming a global champion in the area of cyber security," says Fichtl. ”Smartly.io, while initially a European player, became a global market leader during my time there. We need more of these success stories and I feel SoSafe has the potential to see such similar success. I am impressed by the team and the investors behind SoSafe and look forward to working with them," he adds.
“SoSafe’s C-level is brimming with experienced industry leaders, broad-based and complementary competencies, clear lines of responsibility and transparent structures. With Felix, we have gained an outstanding executive who perfectly complements this team," says Hellemann. “His appointment not only demonstrates our growth and our commitment to our customers, but it showcases our ambitions and will help us cement SoSafe as a global leader in cybersecurity awareness,” says Niklas Hellemann, co-founder and CEO of SoSafe.
SoSafe is currently scaling internationally and has recently opened hubs in Amsterdam, London, and Paris to manage new markets.
_______________
About SoSafe
SoSafe empowers organizations to build a security culture and mitigate risk with its GDPR-compliant awareness programs. The company was founded in Cologne, Germany, in 2018 by psychologist and former BCG consultant Niklas Hellemann, Digitalization Expert and previous McKinsey consultant Lukas Schaefer, and seasoned software engineer Felix Schuerholz. Today, it serves more than 2000 customers worldwide and is the market leader in security awareness and training in the DACH region. As one of the leading second-generation awareness platforms, they are powered by behavioral science and smart algorithms and focus on user engagement and the needs of the customer. In doing so, SoSafe delivers engaging, personalized learning experiences and smart attack simulations that turn employees into active assets against online threats. The SoSafe team now consists of more than 350 employees at five locations: Cologne (headquarters), Amsterdam, Berlin, London, and Paris.
Website: www.sosafe-awareness.com/
LinkedIn: www.linkedin.com/company/sosafe-cyber-security/mycompany/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220706005071/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
